Fluticasone/salmeterol
Combination of | |
---|---|
Fluticasone propionate | Glucocorticoid |
Salmeterol | Long-acting β2 agonist (LABA) |
Clinical data | |
Trade names | Advair, Seretide, Cyplos, others |
AHFS/Drugs.com | FDA Professional Drug Information |
MedlinePlus | a699063 |
License data | |
Pregnancy category |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
KEGG | |
(verify) |
Fluticasone/salmeterol, sold under the brand name Advair among others, is a
Common side effects include thrush, headache, and cough.[3] Serious side effects may include worsening asthma, anaphylaxis, seizures, and heart problems.[3] Safety in pregnancy and breastfeeding is unclear.[4] Fluticasone, a corticosteroid, works by decreasing inflammation while salmeterol, a long-acting beta-adrenoceptor agonist (LABA), works by activating beta-2 adrenergic receptors.[3]
The combination was approved for medical use in the United States in 2000.[3] A generic version was approved in the United States in 2019.[5] In 2021, it was the 64th most commonly prescribed medication in the United States, with more than 10 million prescriptions.[6][7]
Medical uses
Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination which decreases inflammation in the lungs. This leads to improvement in breathing. Salmeterol, an LABA, treats constriction of the airways. The combination of both is meant to be used as maintenance therapy and not as a rescue therapy for sudden symptoms.
Side effects
The common side effects of this combination are those of its individual drugs. For instance, the use of inhaled corticosteroids is associated with oral candidiasis, commonly known as yeast infection or thrush. Rinsing the mouth with water after inhaling the medication decreases the risk of developing this condition.
While the use of inhaled steroids and LABA are recommended for the resulting improvement in control of symptoms of asthma,[8] concerns have been raised that salmeterol may increase the risk of death due to asthma, and this additional risk is not reduced by the addition of inhaled steroids.[9] Other side effects from this drug combination may include increased blood pressure, change in heart rate, an irregular heartbeat, increased risk of osteoporosis, cataracts, and glaucoma.[10] Studies have demonstrated the safety of inhaled fluticasone propionate in children. A systematic review published in 2013 found no significant adverse effect on the function of the hypothalamic–pituitary–adrenal axis, growth, and bone mineral density in asthmatic children when inhaled fluticasone is used for up to three months.[11]
Mechanism of action
Fluticasone/salmeterol contains
Society and culture
Legal status
On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Seffalair Spiromax, intended for the treatment of asthma.[13] The applicant for this medicinal product is Teva B.V.[13] The CHMP also recommended the granting of a marketing authorization for the duplicate product BroPair Spiromax.[14] Seffalair Spiromax and BroPair Spiromax were both approved for medical use in the European Union in March 2021.[15][16][17][18]
Generic equivalents
In January 2019, the FDA granted Mylan N.V. the first generic approval for Advair Diskus.[19]
Civil settlements
In 2012, Advair was part of a larger civil settlement agreement between
References
- ^ "Seroflo Multihaler (Cipla Australia Pty Ltd)". Department of Health and Ages Care. Retrieved 1 April 2023.
- ^ ISBN 9780857113382.
- ^ a b c d "Fluticasone and Salmeterol inhalation - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 4 March 2019.
- ^ "Fluticasone / salmeterol Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ Office of the Commissioner. "Press Announcements - FDA approves first generic Advair Diskus". www.fda.gov. Retrieved 1 February 2019.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Fluticasone; Salmeterol - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ "Guideline 101: British Guideline on the Management of Asthma". British Thoracic Society & Scottish Intercollegiate Guidelines Network (SIGN). Archived from the original on 18 April 2015.
- PMID 16754916.
- ^ "US fluticasone propionate/Salmeterol label" (PDF). FDA. April 2016.
- PMID 23859431.
- ^ "Advair Diskus 100/50" (PDF). Food and Drug Administration. Retrieved 30 October 2019.
- ^ a b "Seffalair Spiromax: Pending EC decision". European Medicines Agency (EMA). 1 February 2021. Retrieved 1 February 2021.
- ^ "BroPair Spiromax: Pending EC decision". European Medicines Agency (EMA). 1 February 2021. Retrieved 1 February 2021.
- ^ "Seffalair Spiromax EPAR". European Medicines Agency (EMA). 25 January 2021. Retrieved 23 August 2021.
- ^ "BroPair Spiromax EPAR". European Medicines Agency (EMA). 25 January 2021. Retrieved 23 August 2021.
- ^ "Seffalair Spiromax Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ "BroPair Spiromax Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ "FDA approves first generic Advair Diskus". U.S. Food and Drug Administration (FDA). 24 March 2020.
- ^ "GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data". Department of Justice: Office of Public Affairs. 2 July 2012.